- Company
- Asthma drug 'Monterizine' sales rise despite generic entries
- by Kim, Jin-Gu Nov 12, 2024 05:51am
- Hanmi's asthma treatment, 'Monterizine,' successfully expanded its prescription sales over 10% Year-over-Year (YoY), despite the release of generics. Generic drugs had been listed for reimbursement in October 2023. The analysis suggests that Monterizine's continued sales expansion is because generic prices have not been reduced and, it mainta
- Company
- 'Vabysmo' for macular deg associated RVO indication expected
- by Eo, Yun-Ho Nov 12, 2024 05:51am
- The first bispecific antibody for eye diseases, 'Vabysmo,' is soon to be approved in South Korea for its indication of treating macular degeneration associated retinal vein occlusion (RVO). According to industry sources, Roche Korea's Vabysmo (faricimab) is being reviewed by the Ministry of Food and Drug Safety (MFDS) for its indication ex
- CG Invites' personalized cancer vaccine shows promise
- by 강은희 Nov 12, 2024 05:51am
- CG Invites (Co-CEOs Chung In-chul and Oh Su-yeon), a frontrunner in digital genomics-driven drug development, announced groundbreaking preclinical results for their personalized cancer immunotherapy vaccine on the 11th. Cancer vaccines epitomize personalized medicine, harnessing tumor-specific antigens to activate the patient's immune system
- Opinion
- [Reporter's View] Patience is required to foster K-Bios
- by Whang, byung-woo Nov 12, 2024 05:51am
- The performance of the domestic pharmaceutical bio industry is being evaluated with the approaching end of 2024. This year, the increased influence of domestic companies in the fields of biosimilars and CDMOs (contract development and manufacturing) and the technology transfer performance of bio ventures have been positively evaluated.&1
- Company
- Generic companies seek early entry into KRW 100 bil Tagrisso
- by Kim, Jin-Gu Nov 12, 2024 05:51am
- Patent challenges to Tagrisso (osimertinib), a non-small cell lung cancer treatment that posts annual sales of KRW 110 billion, are expanding.&160; The companies that have filed patent challenges seek to first evade the product patent, which expires in 2035, and then launch generics early after November 2033, when the substance patent ex
- Policy
- NHIS-Roche enters pricing negotiations for Perjeta’s reimb
- by Lee, Tak-Sun Nov 12, 2024 05:50am
- Roche has started drug price negotiations with the National Health Insurance Service for its breast cancer drug Perjeta (pertuzumab). The negotiations are expected to be held on the drugs whose reimbursement standards were set by the Cancer Disease Review Committee in May. According to industry sources on the 11th, the NHIS recently inc
- Company
- Will Lorviqua be reimbursed as a first-line therapy in KOR?
- by Eo, Yun-Ho Nov 11, 2024 05:49am
- Whether progress will be made in the insurance reimbursement discussions for the ALK antitumor drug Lorviqua is gaining attention. The health authorities recently said they would “promptly start discussions” on the need to expand coverage of the ALK-positive NSCLC drug Lorviqua (lorlatinib) to the first-line. Lorviqua is currently in
- Company
- Companies copromote products at Hypertension Seoul 2024
- by Kim, Jin-Gu Nov 11, 2024 05:49am
- Pharmaceutical and biotech companies with hypertension drugs have gathered at the Conrad Seoul Hotel in Yeouido, Seoul on the 8th. Industry officials, who set up promotional booths at the Korean Society of Hypertension's fall conference (Hypertension Seoul 2024), distributed pamphlets to doctors at the event and introduced the features of t
- Company
- 'Voranigo' for malignant brain tumor expected to land in KOR
- by Eo, Yun-Ho Nov 11, 2024 05:49am
- 'Voranigo,' a new therapy for malignant brain tumors in over twenty years, is anticipated to be brought to South Korea. Sources said that Servier has recently filed an approval application for Voranigo (vorasidenib). Earlier in September, the Ministry of Food and Drug Safety (MFDS) assigned Voranigo an Orphan Drug Designation (ODD).
- Company
- K-Bios showcases new ADC drugs on the international stage
- by Son, Hyung Min Nov 11, 2024 05:49am
- The domestic pharma and biotech industry is speeding up the development of new antibody-drug conjugates (ADCs), unveiling their clinical results. At the 'World ADC 2024' that was held in San Diego, U.S. for 4 days from the 4th of this month, domestic pharmaceutical bio companies including Celltrion, LigaChem Biosciences, and ABL Bio revealed
